Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Poly cystic ovary syndrome (PCOS) is a disease which is prevalent in women of reproductive age facing obesity along with increased risk of type-2 diabetes and high cholesterol levels. The genetically determined cause of the PCOS includes disturbed levels of insulin and androgens. Standardized fenugreek seed extract (Furocyst) contains compounds such as saponins & flavonoids which act on the insulin and indirectly helps to regulate the androgen levels in the body.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Premenopausal women between 18-45 years of age and BMI less than 42
Diagnosed with PCOS
Adequate hepatic, renal and hematological functions
Patients willing to give informed consent in writing
Post menopausal women
Women with hysterectomy
Patients with congenital adrenal hyperplasia
Patients suffering from Cushing's syndrome
Patients diagnosed with androgen secreting tumors
Patients with thyroid dysfunction (T3, T4 level is higher than that in normal women of reproductive age)
Patients with Hypo-gonadotropic and Hypo-gonadism (central origin of ovarian dysfunction)
Pregnancy or desire for pregnancy or lactating mothers